# US 2010/0168159 A1 · Hetero compound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168159 A1
- Document ID: US20100168159A1
- Status: Published application
- Kind: A1
- Application number: 12/696,327
- Filed: 2010-01-29
- Published: 2010-07-01
- Earliest claimed: 2006-04-03
- Assignees: Astellas Pharma Inc.
- Inventors: Hironori Harada; Kazuyuki Hattori; Kazuya Fujita; Masataka Morita; Sunao Imada; Yoshito Abe; Hiromichi Itani; Tatsuaki Morokata; Hideo Tsutsumi
- Web page: https://patentgrep.com/patent/US20100168159A1

## CPC

- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 471/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

[Problems] To provide a useful compound as an active ingredient for a preventing and/or treating agent for rejection in the transplantation of an organ, bone marrow, or a tissue, an autoimmune disease, or the like, which has an excellent S1P1 agonist activity. [Means for solving] Since the compound of the invention has an S1P1 agonist activity, it is useful as an active ingredient for a treating or preventing agent for a disease caused by unfavorable lymphocytic infiltration, for example, an autoimmune disease such as graft rejection in the transplantation of an organ, bone marrow, or a tissue, a graft-versus-host disease, rheumatic arthritis, multiple sclerosis, systemic lupus erythematosus, a nephrotic syndrome, encephalomeningitis, myasthenia gravis, pancreatitis, hepatitis, nephritis, diabetes, pulmonary disorder, asthma, atopic dermatitis, inflammatory bowel disease, atherosclerosis, ischemia-reperfusion injury, or an inflammatory disease, and further, a disease caused by the abnormal growth or accumulation of cells such as cancer and leukemia.

## Claims

### Claim 1

A compound represented by the formula (I):
or a pharmaceutically acceptable salt thereof,
wherein the ring A is
X is a single bond, —CH2—, —NR3, —O—, —S—, —S(═O)—, or —S(═O)2—;
R1 is —H, halogen, aryl, heteroaryl, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl, (C3-C8)heterocycloalkyl, or optionally substituted (C1-C6)alkyl or optionally substituted (C2-C6)alkenyl, each of which may contain halogen, —CONH2, aryl, or (C3-C8)cycloalkyl as a subsistutent;
R2 is —CN, —O—(C1-C6)alkyl, —C(═O)H or halogen, or optionally substituted (C1-C6)alkyl which may be substituted with halogen or —OH, wherein when —X— is a single bond, R1 and R2 may in combination form a 5-membered ring and may further contain (C1-C6) alkyl as an optional substituent;
R3 is —H, wherein R3 may form morpholino, 1-pyrrolidinyl or 3,4-dehydropiperidin-1-yl, together with R1 and nitrogen;
R4 is
wherein any one of the bonds from the R4 ring is bound to the oxadiazole ring;
R5 is —H, R0—(C1-C6)alkyl, R0—(C1-C6)alkyl-O—, R0—(C1-C6)alkyl-C(═O)—, R0—(C1-C6)alkyl-S(═O)2—, R0—O—(C1-C6)alkyl-, R0—C(═O)—(C1-C6)alkyl-, R0—S(═O)2—(C1-C6)alkyl-, (C2-C6)alkenyl-, —C(═O)H, —ORX, —S(═O)2RX, halogen, ═O, —NRXRY, or —C(═O)NRXRY, wherein R0—(C1-C6)alkyl means (C1-C6)alkyl which may be substituted with at least one group each selected from R0, wherein R0 is —CN, —C(═O)NRXRY, —NHRX, —SRX, —S(═O)2RX or —ORX; and
RX and RY may be the same or different and are —H, or (C1-C6)alkyl which may be optionally substituted with —OH, —NH2 (which may be protected with a protecting group) or heteroaryl, wherein RX may form (C3-C8)heterocycloalkyl, together with RY and nitrogen.

### Claim 2 (depends on 1)

The compound according to claim 1, which is represented by the formula (II):
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

The compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein R1 is (C1-C6)alkyl which may contain halogen as an optional substituent.

### Claim 4 (depends on 2)

The compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein R2 is —CN, halogen, or (C1-C6)alkyl which may be optionally substituted with halogen or —OH.

### Claim 5 (depends on 2)

The compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein R5 is H, or (C1-C6)alkyl which may be optionally substituted with at least one —C(═O)NRXRY.

### Claim 6 (depends on 2)

The compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein X is a single bond, —CH2— or —O—.

### Claim 7 (depends on 2)

The compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein R4 is a following ring;
wherein any one of the bonds from the R4 ring is bound to the oxadiazole ring.

### Claim 8

A compound selected from the following, or a pharmaceutically acceptable salt thereof:
4-{5-[3-(trifluoromethyl)-4-(2,2,2-trifluoro-1-methylethoxy]phenyl)-1,2,4-oxadiazol-3-yl)-1H-pyrrolo[2,3-b]pyridine hydrochloride;
2-[4-(5-{5-chloro-6-[(1S)-2,2,2-trifluoro-1-methylethoxy]pyridine-3-yl]-1,2,4-oxadiazol-3-yl)-1H-indol-1-yl)acetamide; or
2-[4-(5-{5-chloro-6-[2-fluoro-1-(fluoromethyl)ethoxy]pyridin-3-yl}-1,2,4-oxadiazol-3-yl)-1H-indol-1-yl)acetamide;

### Claim 9

A compound selected from the group consisting of:
4-{5-[3-(trifluoromethyl)-4-(2,2,2-trifluoro-1-methylethoxy]phenyl)-1,2,4-oxadiazol-3-yl)-1H-pyrrolo[2,3-b]pyridine hydrochloride;
2-[4-(5-{5-chloro-6-[(1S)-2,2,2-trifluoro-1-methylethoxy]pyridine-3-yl]-1,2,4-oxadiazol-3-yl)-1H-indol-1-yl)acetamide; and
2-[4-(5-{5-chloro-6-[2-fluoro-1-(fluoromethyl)ethoxy]pyridin-3-yl}-1,2,4-oxadiazol-3-yl)-1H-indol-1-yl)acetamide;

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A pharmaceutical composition comprising a compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof as an active ingredient, together with a pharmaceutically acceptable carrier.

### Claim at position 11

11-13. (canceled)

### Claim 14 (depends on 10)

A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt according to claim 10, which is an S1P1 agonist.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A method for treating and/or preventing rejection in transplantation of organ/bone marrow/tissue in human or animal, graft-versus-host disease rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, nephrotic syndrome, encephalomeningitis, myasthenia gravis, pancreatitis, hepatitis, nephritis, diabetes, asthma, atopic dermatitis, inflammatory bowel disease, atherosclerosis, ischemia-reperfusion injury, cancer, or leukemia, said method comprising administeration of the compound or pharmaceutically acceptable salt according to any one of claims 1 to 8, to a subject suffering from aforementioned disease.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A method for the manufacture of an agent for treating and/or preventing rejection in transplantation of organ/bone marrow/tissue in human or animal, graft-versus-host disease, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, nephrotic syndrome, encephalomeningitis, myasthenia gravis, pancreatitis, hepatitis, nephritis, diabetes, asthma, atopic dermatitis, inflammatory bowel disease, atherosclerosis, ischemia-reperfusion injury, cancer, or leukemia comprising admixing a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 8 with a pharmaceutically acceptable carrier.

### Claim at position 15

17-18. (canceled)
